This chapter provides a comprehensive overview of immune checkpoint expression and function in asthma. It begins by introducing asthma as a heterogeneous airway disease and its classification into T2-high and T2-low phenotypes. The chapter then explores the immunopathogenesis of asthma, discussing the roles of various immune cells, including mast cells, eosinophils, and innate lymphoid cells (ILCs). Part of the chapter is dedicated to examining specific immune checkpoint molecules, including CTLA-4, PD-1, TIM-3, CD200-CD200R, VISTA, BTLA, and TIGIT. For each checkpoint, the chapter explores its expression patterns in asthma patients, its impact on disease severity, and its potential as a therapeutic target. The content covers both human studies and animal models, providing a balanced view of the current understanding in the field. It also addresses the complex interplay between different checkpoint molecules and their effects on various immune cell populations, particularly T cells and ILC2s. By presenting a comprehensive review, this chapter provides a robust foundation for understanding the current research on immune checkpoints in asthma and their potential impact on future therapeutic advancements.